Century Therapeutics, Inc. (IPSC) Institutional Ownership

Ownership Summary

Century Therapeutics, Inc. (NASDAQ:IPSC) appears in 45 institutional 13F filings for the quarter ending December 2025.

• Collectively, these holders controlled 29.6% of Century Therapeutics's outstanding shares in December 2025, up from 23.4% in September 2025.
• They increased total shares held in Century Therapeutics by 67.61% from last quarter, and the number of investors in IPSC decreased 37.5% annually.
• Among the 45 funds, 17 bought more Century Therapeutics shares, 12 sold down, and 16 held their ground.
• Altogether, these fund groups held 25.63Mn shares in IPSC by December 2025, up by 10.34Mn shares quarter on quarter, and down 11.37Mn shares year over year.
• TCG Crossover Management, LLC is the top holder of Century Therapeutics as of December 31, 2025, with 17.75Mn shares representing 20.53% of outstanding stock.
• The largest buyers of Century Therapeutics for the quarter ending December 2025 were TCG Crossover Management, LLC (17.75Mn), RA CAPITAL MANAGEMENT, L.P. (17.75Mn), Versant Venture Management, LLC (12.17Mn), Deep Track Capital, LP (9.49Mn), Venrock Adviser, LLC (8.7Mn).
• The largest sales of IPSC for the quarter ending December 2025 came from ACADIAN ASSET MANAGEMENT LLC (939.03K), RENAISSANCE TECHNOLOGIES LLC (442.37K), DAFNA Capital Management LLC (359.23K), SUPERSTRING CAPITAL MANAGEMENT LP (343.66K), GSA CAPITAL PARTNERS LLP (256.36K).
• Per Business Quant, the top 10 investors in IPSC for the quarter ending December 2025 include TCG Crossover Management, LLC (17.75Mn), RA CAPITAL MANAGEMENT, L.P. (17.75Mn), Versant Venture Management, LLC (12.17Mn), Deep Track Capital, LP (9.49Mn), Venrock Adviser, LLC (8.7Mn), Commodore Capital LP (8.7Mn), RTW INVESTMENTS, LP (8.7Mn), Point72 Asset Management, L.P. (5.96Mn), VANGUARD CAPITAL MANAGEMENT LLC (5.69Mn), BALYASNY ASSET MANAGEMENT L.P. (5.02Mn).